Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-10 of 21 (Search time: 0.002 seconds).
previous
1
2
3
next
Item hits:
Preview
Issue Date
Title
Author(s)
2015
KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy
Yeung, D.
;
Tang, C.
;
Vidovic, L.
;
White, D.
;
Branford, S.
;
Hughes, T.
;
Yong, A.
2017
CYP2C8 genotype significantly alters imatinib metabolism in chronic myeloid leukaemia patients
Barratt, D.
;
Cox, H.
;
Menelaou, A.
;
Yeung, D.
;
White, D.
;
Hughes, T.
;
Somogyi, A.
2012
Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia
Yeung, D.
;
Hughes, T.
2012
BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management
Branford, S.
;
Yeung, D.
;
Prime, J.
;
Choi, S.
;
Bang, J.
;
Park, J.
;
Kim, D.
;
Ross, D.
;
Hughes, T.
2014
Achieving the deep molecular response levels required for an imatinib discontinuation trial is strongly associated with the BCR-ABL level at the first qualifying timepoint
Branford, S.
;
Ross, D.
;
Yeung, D.
;
Braley, J.
;
Hughes, T.
;
56th ASH Annual Meeting (6 Dec 2014 - 9 Dec 2014 : San Francisco, California)
2014
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
Branford, S.
;
Yeung, D.
;
Parker, W.
;
Roberts, N.
;
Purins, L.
;
Braley, J.
;
Altamura, H.
;
Yeoman, A.
;
Georgievski, J.
;
Jamison, B.
;
Phillis, S.
;
Donaldson, Z.
;
Leong, M.
;
Fletcher, L.
;
Seymour, J.
;
Grigg, A.
;
Ross, D.
;
Hughes, T.
2010
Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDELL-II trial
Yeung, D.
;
Osborn, M.
;
White, D.
;
Branford, S.
;
Haswell, L.
;
Slader, C.
;
Issa, S.
;
Hiwase, D.
;
Hertzberg, M.
;
Schwarer, A.
;
Filshie, R.
;
Arthur, C.
;
Kwan, Y.
;
Forsyth, C.
;
Ross, D.
;
Mills, A.
;
Grigg, A.
;
Hughes, T.
;
Annual Meeting of the American Society of Hematology (52nd : 2010 : Orlando, Fl.)
2018
Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression
McClure, B.
;
Heatley, S.
;
Kok, C.
;
Sadras, T.
;
An, J.
;
Hughes, T.
;
Lock, R.
;
Yeung, D.
;
Sutton, R.
;
White, D.
2017
Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions
Sadras, T.
;
Heatley, S.
;
Kok, C.
;
Dang, P.
;
Galbraith, K.
;
McClure, B.
;
Muskovic, W.
;
Venn, N.
;
Moore, S.
;
Osborn, M.
;
Revesz, T.
;
Moore, A.
;
Hughes, T.
;
Yeung, D.
;
Sutton, R.
;
White, D.
2013
BCR-ABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance
Parker, W.
;
Yeoman, A.
;
Jamison, B.
;
Yeung, D.
;
Scott, H.
;
Hughes, T.
;
Branford, S.
Discover
Author
14
Branford, S.
9
Ross, D.
9
White, D.
5
Braley, J.
5
Kok, C.
5
Parker, W.
5
Seymour, J.
4
Grigg, A.
4
Hiwase, D.
4
Phillis, S.
.
next >
Subject
9
Leukemia, Myelogenous, Chronic, B...
8
Humans
7
Antineoplastic Agents
6
Fusion Proteins, bcr-abl
5
Benzamides
5
Piperazines
5
Pyrimidines
4
Adult
4
Female
4
Imatinib Mesylate
.
next >
Date issued
1
2019
3
2018
3
2017
1
2016
1
2015
4
2014
5
2013
2
2012
1
2010